S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
NASDAQ:STML

Stemline Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$11.83
0.00 (0.00 %)
(As of 06/10/2020)
Add
Compare
Today's Range
$11.83
$11.83
50-Day Range
$11.83
$11.83
52-Week Range
$3.21
$18.22
Volume1,084 shs
Average Volume1.52 million shs
Market Capitalization$621.21 million
P/E RatioN/A
Dividend YieldN/A
Beta1.78

Receive STML News and Ratings via Email

Sign-up to receive the latest news and ratings for Stemline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Stemline Therapeutics logo

About Stemline Therapeutics

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STML
Employees
92
Year Founded
N/A

Sales & Book Value

Annual Sales
$43.22 million
Book Value
$3.26 per share

Profitability

Net Income
$-76.82 million
Net Margins
-150.30%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$621.21 million
Next Earnings Date
N/A
Optionable
Optionable

MarketRank

Overall MarketRank

1.63 out of 5 stars

Medical Sector

987th out of 1,361 stocks

Pharmaceutical Preparations Industry

480th out of 668 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Stemline Therapeutics (NASDAQ:STML) Frequently Asked Questions

What stocks does MarketBeat like better than Stemline Therapeutics?

Wall Street analysts have given Stemline Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Stemline Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Stemline Therapeutics' earnings last quarter?

Stemline Therapeutics Inc (NASDAQ:STML) posted its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.08. The biopharmaceutical company earned $13.33 million during the quarter, compared to analyst estimates of $13.40 million. Stemline Therapeutics had a negative net margin of 150.30% and a negative trailing twelve-month return on equity of 48.14%.
View Stemline Therapeutics' earnings history
.

Who are Stemline Therapeutics' key executives?

Stemline Therapeutics' management team includes the following people:
  • Dr. Ivan Bergstein, Founder, Pres, CEO & Chairman (Age 53)
  • Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 59)
  • Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 54)
  • Mr. Robert Francomano, Sr. VP & Global Head of Commercial
  • Mr. John A. Salvagno, Sr. VP of Quality & Operations

What other stocks do shareholders of Stemline Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stemline Therapeutics investors own include TG Therapeutics (TGTX), Gilead Sciences (GILD), Viking Therapeutics (VKTX), ZIOPHARM Oncology (ZIOP), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Bausch Health Companies (BHC), FireEye (FEYE), NVIDIA (NVDA) and Sorrento Therapeutics (SRNE).

What is Stemline Therapeutics' stock symbol?

Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."

What is Stemline Therapeutics' stock price today?

One share of STML stock can currently be purchased for approximately $11.83.

How much money does Stemline Therapeutics make?

Stemline Therapeutics has a market capitalization of $621.21 million and generates $43.22 million in revenue each year. The biopharmaceutical company earns $-76.82 million in net income (profit) each year or ($1.83) on an earnings per share basis.

How many employees does Stemline Therapeutics have?

Stemline Therapeutics employs 92 workers across the globe.

What is Stemline Therapeutics' official website?

The official website for Stemline Therapeutics is www.stemline.com.

Where are Stemline Therapeutics' headquarters?

Stemline Therapeutics is headquartered at 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022.

How can I contact Stemline Therapeutics?

Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected].


This page was last updated on 10/16/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.